Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

n, abdominal pain, loss of appetite, vomiting, diarrhea, decreased hemoglobin, abnormal bleeding, nausea, fatigue and rash.

Gleevec is sometimes associated with stomach or intestinal irritation. Gleevec should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including deaths, of stomach or intestinal perforation (a small hole or tear).

If you are experiencing any of the mentioned side effects, please be sure to speak with your doctor immediately.

Do not take any other medications without talking to your doctor or pharmacist first, including Tylenol® (acetaminophen); herbal products (St. John's wort, Hypericum perforatum); Coumadin® (warfarin sodium); rifampin; erythromycin; metoprolol; ketoconazole; and Dilantin® (phenytoin). Taking these with Gleevec may affect how they work, or affect how Gleevec works.  

You should also tell your doctor if you are taking or plan to take iron supplements.  Patients should also avoid grapefruit juice and other foods that may affect how Gleevec works.

About INC424INC424 is an oral inhibitor, of the JAK1 and JAK2 tyrosine kinases. INC424 is being investigated in primary myelofibrosis as well as post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). INC424 is also being investigated in clinical trials for the treatment of polycythemia vera (PV).

Novartis licensed INC424 from Incyte for development and potential commercialization outside the US. Incyte has retained rights for the development and potential commercialization of INC424 in the US. Both the European Commission (EC) and the US Food and Drug Administration (FDA) have granted INC424 orphan drug status for myelofibrosis.

About TasignaTasigna® (nilotinib) 150 mg capsules is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukem
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed... -- DALLAS, November 10, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... Md., Nov. 9, 2010 Most makers of approved ... and meeting targets for postmarketing studies/clinical trials in a ... the U.S. Food and Drug Administration (FDA). ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) The study, based on ...
Cached Medicine Technology:Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 2Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 3Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 4Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 5Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 6Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 7Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 8Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 9FDA: Majority of Drug and Biological Product Makers Meeting Postmarketing Requirements and Commitments 2
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 ALS Ice Bucket Challenge ... and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn and Pete Frates, ... $100,000 to further collaborative efforts among the ALS organizations to find treatments and cures ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ... to. , Instead of risking containment — or even destruction — of products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby ... post that encourages the understanding and treatment of ankle sprains. A common sports ... remedies. This can be dangerous if the condition augments and causes more disruption. ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ), a ... line will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. ... model with Down syndrome, gracing the front pages of publications across the world. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the innovative leader ... Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a compilation ... the benefits of using medication management technologies . , Eldermark’s ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... 8 Brookdale Senior Living Inc. (NYSE: BKD ... disclosed public offering of 13,953,489 shares of common stock, at ... underwriters in the offering exercised in full their option to ... at the public offering price, resulting in net proceeds to ...
... CITY, June 8 Qqest Software Systems today announced that ... and attendance software, as well as the company,s Payroll Services. ... over 5,000 medical procedures each year. Prior to adopting Qqest,s ... manual time clock and paper time cards to track time. ...
... ("Scient,x" or the "Company") announced today that it has ... Corporation and an incremental equity investment by the Company,s ... equity package amounts to $12.5 million. Terms were ... CEO of Scient,x stated, "I am excited that Scient,x ...
... Year-Long Phase 2 Diabetes Study Results Presented at ADA Annual ... VIVUS, Inc. (Nasdaq: VVUS ), a biopharmaceutical ... obesity, diabetes and sexual health, today announced that data from ... with type 2 diabetes are being highlighted in an oral ...
... expert cautions, , MONDAY, June 8 (HealthDay News) -- New ... might cause their disease to relapse may be reassured by a ... women. , The study, in the June 8 issue of ... with multiple sclerosis (MS) who breast-fed exclusively for two months or ...
... strong among those in their 20s, study finds, , MONDAY, ... colorectal cancer rates in the United States in the past ... on the upswing among people younger than 50. , The ... now running annually at 2.8 percent and 2.2 percent among ...
Cached Medicine News:Health News:Brookdale Announces Completion of Follow-On Offering 2Health News:Brookdale Announces Completion of Follow-On Offering 3Health News:Brookdale Announces Completion of Follow-On Offering 4Health News:Brookdale Announces Completion of Follow-On Offering 5Health News:Colorado Gastroenterology Chooses Qqest's TimeForce, Payroll Services 2Health News:Scient'x Groupe, S.A. Announces Completion of Credit Facility and Incremental Capital Infusion 2Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 2Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 3Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 4Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 5Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 6Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 7Health News:Breast-feeding OK for Most Moms with MS 2Health News:Breast-feeding OK for Most Moms with MS 3Health News:Colorectal Cancer Rates Rising for Under 50 Set 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 3
Test for AFP...
Test for AFP...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Medicine Products: